|Biomerica introduces a Cat Allergy Test
|Biomerica introduces a new 15 minute home test for allergies to Cats and receives CE mark approval for home use
Newport Beach, California – December 18, 2007 -- Biomerica, Inc. (OTC BB: BMRA) has introduced a new 15 minute home test for allergy to cats and announced that it received CE mark approval to market and sell the product directly to consumers through drug stores in the European Union. The product will be marketed under the Fortel® Cat allergy test brand.
Approximately 10 million people in the US are allergic to cat dander, the most common pet allergy. Cat allergies are about twice as common as dog allergies. Each year, allergies account for more than 17 million outpatient office visits in the United States. The annual cost of allergies is estimated to be nearly $7 billion. Allergy is the 5th leading chronic disease in the U.S. among all ages, and the 3rd most common chronic disease among children under 18 years old.
“Consumer’s will now be able to screen for allergies to cats in the privacy of their own home. The CE regulatory approval allows us to sell our product to drugstores and other retailers throughout Europe,” said Zackary Irani, CEO of Biomerica. “We are entering into discussions with several distributors in various European countries”
Biomerica’s Fortel Cat allergy test utilizes an advanced technology that requires only a drop of a persons’ blood with results in 15 minutes. The Fortel® Cat Allergy Test is a part of BIOMERICA’s line of easy to use tests designed to detect diseases before they become catastrophic, incurable or costly to treat.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA. The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.